NEWFree ROI Calculators — quantify what prior auth and siloed data are costing your organization.Prior Auth ROI Siloed Data ROI
HL7 v2Segment4 min read

HL7 PDC Segment: Product Detail Country

The PDC (Product Detail Country) segment describes a product as it is marketed in a specific country. It carries the manufacturer or distributor, the country of marketing authorisation, the brand and generic names, model and catalogue identifiers, and shelf-life dates — the regulatory fingerprint of the product implicated in a post-market surveillance report.

Purpose

PDC tells the receiving regulator exactly which national variant of a product was involved in an adverse experience. The same medicine or device is often marketed under different brand names, package configurations, or marketing-authorisation IDs in different countries; PDC pins those facts down so that the report can be matched to the correct registration dossier.

Used in

PDC appears in product-experience / post-market surveillance PEX messages reporting adverse drug or device events to regulators such as the FDA, EMA, or MHRA. A PEX transaction may include several PDC segments when the same product is registered in multiple jurisdictions or when several products are implicated.

Field-by-field

Each row below reflects the HAPI HL7 v2.5.1 javadoc for PDC. Required fields are marked R; everything else is optional. Repeating fields are flagged Y. Data type names link to their reference page; lengths are not standardised at the segment level for v2.5.1 and are shown as "—".

SeqNameData TypeLengthReqRepeatTable #Description
PDC-1Manufacturer/DistributorxonRYOrganisation marketing the product
PDC-2CountryceRCountry of marketing authorisation
PDC-3Brand NamestRBrand name as marketed in country
PDC-4Device Family NamestOFamily or product line name
PDC-5Generic NameceOCoded generic or non-proprietary name
PDC-6Model IdentifierstOYManufacturer model identifier
PDC-7Catalogue IdentifierstOCatalogue or part number
PDC-8Other IdentifierstOYAdditional product identifiers
PDC-9Product CodeceORegulatory product classification code
PDC-10Marketing BasisidOHL70330Regulatory basis for marketing
PDC-11Marketing Approval IDstOMarketing authorisation identifier
PDC-12Labeled Shelf LifecqOShelf life as printed on the label
PDC-13Expected Shelf LifecqOManufacturer's expected shelf life
PDC-14Date First MarketedtsODate product first sold in country
PDC-15Date Last MarketedtsODate product withdrawn from market

Examples

Minimal

A PDC with only the three required fields — manufacturer, country, and brand name.

PDC|Helios Pharmaceuticals^^L|US^United States^ISO3166|Cardiozen

Fully populated

PDC|Helios Pharmaceuticals^^L|US^United States^ISO3166|Cardiozen|Cardiozen XR|N02BE01^Metoprolol^ATC|CZ-50-XR~CZ-100-XR|CAT-50441|NDC-71744-0050-1|N|NDA-214412|24^months^UCUM|36^months^UCUM|20180915000000|

Annotated breakdown

PDC
 |Helios Pharmaceuticals^^L         PDC-1  Manufacturer (required)
 |US^United States^ISO3166          PDC-2  Country (required)
 |Cardiozen                         PDC-3  Brand name (required)
 |Cardiozen XR                      PDC-4  Device/product family
 |N02BE01^Metoprolol^ATC            PDC-5  Generic name (coded)
 |CZ-50-XR~CZ-100-XR                PDC-6  Model identifier (repeats)
 |CAT-50441                         PDC-7  Catalogue identifier
 |NDC-71744-0050-1                  PDC-8  Other identifier
 |N                                 PDC-9  Product code (regulatory)
 |N                                 PDC-10 Marketing basis (NDA)
 |NDA-214412                        PDC-11 Marketing approval ID
 |24^months^UCUM                    PDC-12 Labeled shelf life
 |36^months^UCUM                    PDC-13 Expected shelf life
 |20180915000000                    PDC-14 Date first marketed
 |                                  PDC-15 Date last marketed (still on market)

In context — PEX message excerpt 1

A PEX report identifying a US-marketed cardiac drug implicated in a hypotensive episode.

MSH|^~&|MEDWATCH|CLINIC-OH|FDA-AERS|FDA|20260601120000||PEX^P07^PEX_P07|MSG00012741|P|2.5.1
EVN|P07|20260601120000
PID|1||PT-44871^^^CLINIC-OH^MR||Okafor^Adaeze^M||19620318|F
PES|Riverford Cardiology^^L|Adekoya^Tomi^J^^Dr.|140 Clinic Way^^Riverford^OH^45402^USA|^WPN^PH^^^937^5550199|SE-2026-7741|1|||20260601090500|20260601120000|I|P|R
PEO|AE-2026-7741^Severe Hypotension^L|R55^Syncope^I10|20260601084500
PCR|N02BE01^Metoprolol^ATC|P|||20260601083000
PDC|Helios Pharmaceuticals^^L|US^United States^ISO3166|Cardiozen|Cardiozen XR|N02BE01^Metoprolol^ATC|CZ-50-XR|CAT-50441|NDC-71744-0050-1||N|NDA-214412|24^months^UCUM|36^months^UCUM|20180915000000

In context — PEX message excerpt 2

A PEX report covering an infusion pump device involved in an over-delivery event in Canada.

MSH|^~&|SAFETY|VENDOR-MFR|HC-CV|HEALTH-CANADA|20260418161500||PEX^P07^PEX_P07|MSG00012088|P|2.5.1
EVN|P07|20260418161500
PID|1||PT-77321^^^HOSP-ON^MR||Singh^Rohan^||19770212|M
PES|MediFlow Devices Canada^^L|Nguyen^Phuc^^^Ms.|22 Bayfront Rd^^Toronto^ON^M5J2N8^CAN|^WPN^PH^^^416^5550188|SE-2026-9088|1|Pump over-delivered 18 mL bolus||20260415130000|20260418160000|I|N|R
PEO|AE-2026-9088^Drug Over-Delivery^L|T88.7^Adverse effect of drug^I10|20260415132000
PCR|DEV-INF-PUMP^Infusion pump^L|D|||20260415130000
PDC|MediFlow Devices Inc^^L|CA^Canada^ISO3166|FlowMaster|FlowMaster 4000|DEV-INF-PUMP^Infusion pump^L|FM4000-V3~FM4000-V3A|CAT-FM-4000|LIC-104412|D|D|MDL-104412|36^months^UCUM|60^months^UCUM|20191101000000

Implementation notes

  • PDC-1, PDC-2, and PDC-3 (manufacturer, country, brand name) are required by the standard. Without all three a regulator cannot reliably identify which national registration the report concerns.
  • PDC-6 (Model Identifier) and PDC-8 (Other Identifier) repeat to allow several model or part numbers when the same incident spans configurations.
  • For drug products, PDC-10 typically carries the marketing basis (e.g. NDA) and PDC-11 the approval number; for device products, the equivalent licence or 510(k) number is placed in PDC-11.
  • Leave PDC-15 (Date Last Marketed) empty while the product is still on the market; populate it only after withdrawal.
  • PEO — describes the clinical observation tied to this product.
  • PES — identifies the sender filing the report.
  • PEX message — the trigger event that carries PDC end-to-end.
← Back to HL7 v2 Guide

Ready to Integrate This Into Your Workflow?

Talk to a Vorro expert about implementing HL7 v2 in your specific environment.

Browse HL7 v2 Guides